149506-79-6

Basic information

• Product Name: 4-(dibenzylamino)cyclohexanone
• Synonyms: 4-(Dibenzylamino);4-(dibenzylamino)cyclohexanone;4-(dibenzylamino)cyclohexan-1-one
• CAS NO: 149506-79-6
• Molecular Formula: C₂₀H₂₃NO
• Molecular Weight: 293.40272
• Mol File: 149506-79-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 427.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.20±0.20(Predicted)
• CAS DataBase Reference: 4-(dibenzylamino)cyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(dibenzylamino)cyclohexanone(149506-79-6)
• EPA Substance Registry System: 4-(dibenzylamino)cyclohexanone(149506-79-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 149506-79-6(Hazardous Substances Data)

Usage

General Description

4-(dibenzylamino)cyclohexanone is a chemical compound with a molecular weight of 359.484 g/mol. It is also identified through its CAS number 2973-78-8. This chemical compound is structurally characterized by an amine group attached to a cyclohexanone ring, which is further substituted by benzyl groups. It belongs to the class of compounds known as Benzene and substituted derivatives. As of now, there isn't much information available regarding its usage, safety measures, and potential health effects. Its physical and chemical properties such as melting point, boiling point, solubility in different solvents, and stability under varying conditions also remain largely unknown.

Upstream product

• 4732-69-8 Chloro-oxo-acetic acid 
• 67-68-5 dimethyl sulfoxide 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 79-37-8 oxalyl dichloride 
• 177906-47-7 trans-4-Hydroxycyclohexyldibenzylamine 
• 100-52-7 benzaldehyde 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 103-49-1 dibenzylamine 
• 6850-65-3 p-hydroxycyclohexylamine 
• 100-39-0 benzyl bromide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 100-46-9 benzylamine 

Downstream Products

• 847798-79-2 4-(morpholin-4-yl)cyclohexan-1-amine 
• 755039-80-6 trans-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 755039-87-3 trans-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine 
• 883194-97-6 cis-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine 
• 558442-97-0 (1r,4r)-4-(morpholin-4-yl)cyclohexan-1-amine 
• 876371-18-5 (1s,4s)-4-morpholinocyclohexanamine 
• 1202411-99-1 4-dibenzylamino-1-trifluormethylcycohexanol 
• 1202411-57-1 dibenzyl-(1-oxa-spiro[2.5]oct-6-yl)-amine 
• 1119283-62-3 (trans)-N,N-dibenzyl-4-(4-methylpiperazin-1-yl)cyclohexanamine 
• 883195-12-8 C₂₅H₃₅N₃ 
• 1119283-64-5 C₁₁H₂₃N₃ 
• 1119283-66-7 C₁₆H₃₁N₃O₂ 
• 1119283-68-9 C₁₂H₂₅N₃ 
• 1119284-16-0 C₁₃H₂₅N₃O 

Relevant articles and documents

NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β

We disclose a novel class of 6-Amino-Tetrahydroquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of anticancer drugs. In contrast to topoII-Targeted drugs currently in clinical use, these compounds do not act as topo

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.